B-C Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Default Order
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products descending

Display 15 Products per page

Crestor
$10,000.00
Crestor (rosuvastatin calcium; AstraZeneca/AbbVie/Shionogi) is a member of the statin class of antidyslipidemic drugs, which competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A) reductase.
June 22, 2018
More information
Bempedoic Acid Franchise
$10,000.00
Bempedoic acid is an orally administered small molecule that inhibits fatty acid and cholesterol synthesis.

More information
Cebranopadol
$10,000.00
Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a novel, first-in-class potent analgesic that has a dual mechanism of action as a potent agonist of both the nociceptin/orphanin FQ peptide receptor (NOP) and opioid peptide receptor.
May 31, 2018
More information
Cymbalta
$10,000.00
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since accrued a number of additional indications for Cymbalta, including diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia in the US, and most recently, chronic musculoskeletal pain.

More information
Cotellic
$10,000.00
Cotellic (cobimetinib; Exelixis/Roche) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway.
May 23, 2018
More information
Binimetinibi
$10,000.00
Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK pathway.

More information
Cimzia
$10,000.00
Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and membrane-bound tumor necrosis factor alpha.
May 18, 2018
More information
Bexsero
$10,000.00
Bexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in adolescents and young adults from 10 years through to 25 years of age in the US, and in individuals two months of age and older in the EU.
May 16, 2018
More information
Cosentyx
$10,000.00
Cosentyx (secukinumab; Novartis) is a fully human monoclonal antibody which acts by neutralizing interleukin (IL)-17A. IL-17A is a pro-inflammatory cytokine secreted by activated T cells. It is indicated for the treatment of plaque psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis.

More information
BeneFix
$10,000.00
BeneFIX (Pfizer) is an recombinant factor IX (rfIX) therapy indicated for the control and prevention of bleeding in hemophilia B.
May 4, 2018
More information
Bay 94-9027
$10,000.00
BAY 94-9027 (Bayer) is a long-acting recombinant factor VIII (rfVIII) product under development for the treatment of hemophilia A.

More information
Breo Ellipta
$10,000.00
Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disorder. Fluticasone furoate is an inhaled corticosteroid that activates the glucocorticoid response element and inhibits pro-inflammatory transcription factors such as NFκB, and antigen-induced lung eosinophilia, thereby suppressing inflammation.
February 16, 2018
More information
Cinqair
$10,000.00
Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma.

More information
BMS-986231
$10,000.00
BMS-986231 (Bristol-Myers Squibb/Ligand) is a second-generation prodrug that chemically breaks down to produce nitroxyl (HNO) and an inactive byproduct.
February 15, 2018
More information
Bevyxxa
$10,000.00
Bevyxxa (betrixaban; Portola Pharmaceuticals) is approved in the US for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness.
January 23, 2018
More information

B-C

B-C

Crestor

Bempedoic Acid Franchise

Cebranopadol

Cymbalta

Cotellic

Binimetinibi

Cimzia

Bexsero

Cosentyx

BeneFix

Bay 94-9027

Breo Ellipta

Cinqair

BMS-986231

Bevyxxa